Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,709 | 92 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk Inc | $423.88 | 25 | $0 (2024) |
| ABBVIE INC. | $210.82 | 8 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $158.81 | 11 | $0 (2024) |
| Exact Sciences Corporation | $105.87 | 5 | $0 (2024) |
| Amgen Inc. | $97.24 | 6 | $0 (2024) |
| Gilead Sciences, Inc. | $95.54 | 3 | $0 (2021) |
| Allergan, Inc. | $86.52 | 2 | $0 (2022) |
| Medtronic, Inc. | $63.01 | 1 | $0 (2024) |
| PFIZER INC. | $62.13 | 4 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $55.12 | 4 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $483.67 | 26 | Exact Sciences Corporation ($85.68) |
| 2023 | $368.12 | 22 | Novo Nordisk Inc ($160.82) |
| 2022 | $307.19 | 17 | Novo Nordisk Inc ($103.24) |
| 2021 | $382.11 | 16 | AbbVie Inc. ($124.98) |
| 2020 | $113.15 | 7 | Novo Nordisk Inc ($30.21) |
| 2019 | $55.12 | 4 | Boehringer Ingelheim Pharmaceuticals, Inc. ($55.12) |
All Payment Transactions
92 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.31 | General |
| Category: NEUROSCIENCE | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: Gastroenterology | ||||||
| 11/26/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $15.32 | General |
| Category: Obesity | ||||||
| 11/25/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $32.91 | General |
| Category: Oncology | ||||||
| 11/15/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $17.35 | General |
| Category: Inflammation | ||||||
| 11/13/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Cardio-renal | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/21/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $15.49 | General |
| Category: Oncology | ||||||
| 10/17/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.17 | General |
| Category: NEUROSCIENCE | ||||||
| 10/16/2024 | Currax Pharmaceuticals LLC | CONTRAVE (Drug) | Food and Beverage | In-kind items and services | $15.21 | General |
| Category: Obesity | ||||||
| 10/03/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $14.05 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.00 | General |
| Category: Diabetes | ||||||
| 09/05/2024 | Medtronic, Inc. | INTELLIS ADAPTIVESTIM (Device) | Food and Beverage | In-kind items and services | $63.01 | General |
| Category: Spinal Cord Neurostimulation | ||||||
| 08/15/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: Cardio-renal | ||||||
| 08/05/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.91 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/18/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 07/01/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $15.50 | General |
| Category: Cardiovascular | ||||||
| 06/13/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $15.76 | General |
| Category: Inflammation | ||||||
| 05/29/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.19 | General |
| Category: NEUROSCIENCE | ||||||
| 04/25/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.47 | General |
| Category: Respiratory | ||||||
| 02/29/2024 | Novo Nordisk Inc | Ozempic (Drug) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: Diabetes | ||||||
| 02/27/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.40 | General |
| Category: Respiratory | ||||||
| 02/22/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $15.70 | General |
| Category: Inflammation/Rare Disease | ||||||
| 02/21/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $23.23 | General |
| Category: Oncology | ||||||
| 01/23/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $16.94 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 17 | 1,218 | 2,269 | $673,744 | $208,509 |
| 2022 | 18 | 1,058 | 1,650 | $469,479 | $142,294 |
| 2021 | 13 | 667 | 1,101 | $289,710 | $98,489 |
| 2020 | 2 | 55 | 57 | $9,450 | $4,152 |
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 203 | 757 | $213,338 | $75,072 | 35.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 297 | 678 | $241,727 | $65,136 | 26.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 150 | 150 | $53,802 | $20,621 | 38.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 95 | 98 | $53,145 | $14,164 | 26.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 136 | 211 | $53,433 | $13,868 | 26.0% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 63 | 65 | $19,073 | $6,232 | 32.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $14,754 | $3,595 | 24.4% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 19 | 19 | $8,702 | $3,330 | 38.3% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 21 | 21 | $2,313 | $1,511 | 65.3% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 47 | 47 | $2,525 | $939.06 | 37.2% |
| 87811 | Detection test by immunoassay with direct visual observation for severe acute respiratory syndrome coronavirus 2 (covid-19) | Office | 2023 | 15 | 19 | $1,178 | $770.45 | 65.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 57 | 61 | $2,794 | $731.60 | 26.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 22 | 22 | $1,100 | $723.14 | 65.7% |
| 87804 | Detection test by immunoassay with direct visual observation for influenza virus | Office | 2023 | 15 | 38 | $1,900 | $616.36 | 32.4% |
| 87426 | Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus | Office | 2023 | 15 | 17 | $1,515 | $588.54 | 38.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 11 | 11 | $1,735 | $532.51 | 30.7% |
| 81002 | Urinalysis, manual test | Office | 2023 | 20 | 23 | $710.49 | $78.43 | 11.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 259 | 701 | $246,752 | $66,735 | 27.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 170 | 170 | $61,200 | $24,028 | 39.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 182 | 265 | $66,250 | $19,116 | 28.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 69 | 121 | $32,912 | $10,360 | 31.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 47 | 48 | $25,296 | $7,966 | 31.5% |
| 99495 | Transitional care management services for problem of moderate complexity | Office | 2022 | 16 | 18 | $10,242 | $3,207 | 31.3% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 38 | 38 | $2,653 | $2,514 | 94.7% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2022 | 11 | 11 | $5,038 | $1,961 | 38.9% |
About Dr. Laith Qumei, M.D
Dr. Laith Qumei, M.D is a Internal Medicine healthcare provider based in Oakhurst, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/28/2017. The National Provider Identifier (NPI) number assigned to this provider is 1316479553.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Laith Qumei, M.D has received a total of $1,709 in payments from pharmaceutical and medical device companies, with $483.67 received in 2024. These payments were reported across 92 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($1,709).
As a Medicare-enrolled provider, Qumei has provided services to 2,998 Medicare beneficiaries, totaling 5,077 services with total Medicare billing of $453,444. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Location Oakhurst, NJ
- Active Since 03/28/2017
- Last Updated 12/29/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1316479553
Products in Payments
- Ozempic (Drug) $289.09
- UBRELVY (Drug) $181.57
- Rybelsus (Drug) $121.56
- Cologuard Collection Kit (Device) $105.87
- BREZTRI (Drug) $66.62
- INTELLIS ADAPTIVESTIM (Device) $63.01
- KRYSTEXXA (Biological) $57.58
- Otezla (Drug) $50.05
- FARXIGA (Drug) $48.80
- JARDIANCE (Drug) $44.91
- VRAYLAR (Drug) $41.67
- FREESTYLE LIBRE 3 (Device) $36.35
- Kerendia (Drug) $34.87
- ENTRESTO (Drug) $31.66
- Repatha (Biological) $31.49
- PAXLOVID (Drug) $30.53
- AIRSUPRA (Drug) $29.87
- JANUVIA (Drug) $28.44
- CONTRAVE (Drug) $28.07
- INJECTAFER (Drug) $27.35
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Oakhurst
Dr. John Ciciarelli, Md, MD
Internal Medicine — Payments: $42,609
Dr. Aleksey Kretov, Md, MD
Internal Medicine — Payments: $18,333
Charles Peeples, Md, MD
Internal Medicine — Payments: $9,690
Dr. Richard Mojares, M.d, M.D
Internal Medicine — Payments: $6,285
Dr. Dharmesh Kaswala, Md, MD
Internal Medicine — Payments: $6,113
Reza Akhtar, Md, MD
Internal Medicine — Payments: $6,097